The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e. g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10,e. g.cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.本發明提供胜肽,具以下SEQ ID NO之胺基酸序列:SEQ ID NO: 19、22、30、34、344、358、41、44、46、48、78、376、379、80、100、101、110、111、387、112、394、114、116、117、121、395、133、135、137、426、174、178、186、194、196、202、210、213、214、217、223、227、228、233、254、271、272或288,及具上述胺基酸序列之胜肽,其中一、二或數個(例如,最多五個)胺基酸經取代、刪除或加成,惟該等胜肽具細胞毒性T細胞誘導能力。本發明尚提供藥物,用於治療或預防與過度表現CDH3、EPHA4、ECT2、HIG2、INHBB、KIF20A、KNTC2、TTK及/或URLC10相關之疾病,例如癌症,包含一種以上此等胜肽作為有效成分。本發明之胜肽更作為疫苗為有用。
